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Abstract: The prevalence of metabolic disorders, such as type 2 diabetes (T2D), obesity, and
non-alcoholic fatty liver disease (NAFLD), which are common risk factors for cardiovascular disease
(CVD), has dramatically increased worldwide over the last decades. Although dietary habit is the
main etiologic factor, there is an imperfect correlation between dietary habits and the development of
metabolic disease. Recently, research has focused on the role of the microbiome in the development
of these disorders. Indeed, gut microbiota is implicated in many metabolic functions and an altered
gut microbiota is reported in metabolic disorders. Here we provide evidence linking gut microbiota
and metabolic diseases, focusing on the pathogenetic mechanisms underlying this association.
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1. Introduction
According to the World Health Organization cardiovascular disease (CVD) remains the leading
cause of death in Western countries, accounting for about 20 million deaths/year worldwide [1].
Nevertheless, the prevalence of metabolic diseases, such as type 2 diabetes (T2D), obesity, and
non-alcoholic fatty liver disease (NAFLD), which are common risk factors for CVD, has dramatically
increased over the last decades worldwide.
Both genetic susceptibility and environmental factors contribute to cardio-metabolic pathogenesis.
Unfortunately, despite the introduction of new extensive investigation on genetic determinants, such as
large-scale genome-wide association study (GWAS), only a few cases can be assigned to genetic
factors [2,3]. Thus, the environmental component seems to be primarily involved in CVD burden.
The largest environmental exposure is food that we take into our intestine in kilogram quantities
every day. However, there is an imperfect correlation between dietary habits and the development of
metabolic disease. Diet, on the other hand, is known to deeply alter the microbiota composition in the
gut. Therefore, recent evidence focused on the role of the gut microbiota in cardio-metabolic disorders
and growing interest is aimed to modulate the gut microbiota as a therapeutic strategy.
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2. Gut Microbiota
The human gut harbors an enormously complex, dynamic, and vast microbial community that
is composed mainly of bacteria, but also includes viruses, fungi, protozoa, and archaea [4]. The gut
microbiota is estimated to consist of at least 1014 bacteria and archaea, including more than 1100 species
and 150-fold more genes than our own host genomes [5].
The introduction of culture-independent methods to study the microbial community revealed the
complexity of the gut microbiota. The human gut microbiota is dominated by bacteria belonging to four
major phyla: Firmicutes, Bacteroidetes, Actinobacteria (representing >95% of the total microbiota), and
Proteobacteria [6]. Interestingly, Actinobacteria and Proteobacteria are more abundant in childhood,
while Firmicutes and Bacteroidetes are prevalent in adulthood.
The fetal human gut was supposed to be sterile at birth; however, very recently, it has been
reported that there is a passage of microbes between the mother and the fetus through the placenta.
The most important colonization of the gastrointestinal tract starts suddenly after the birth and depends
on delivery type, maternal flora, environment hygiene, and infant diet. During the first years of life,
the gut microbiota composition is widely shifting and changeable, while it stabilizes when the infant
reaches 1–3 years of age [7]. Microbial density increases from the proximal to the distal gut, and along
the mucosal-lumen axis [8]. Similarly to bacterial density, microbial diversity also increases along the
same axis.
The composition of the gut microbiota is dynamically influenced by several host factors, including
diet, lifestyle, antibiotics, and genetic background. In a C57B/L6J mouse model, the use of antibiotics,
in early life, alters the host metabolism and adiposity by a modification of the microbiome [9].
Another study described that the maternal administration of antibiotics during the last six months
before the pregnancy or the early infancy is related to reduced bacterial diversity of the feces of the
neonate, decreased levels of Lactobacilli and Bifidobacteria, and increased risk of childhood obesity [10].
Diet seems to play a critical role, being linked to quantitative and qualitative modifications of the
microbiota composition. A study comparing the gut microbiota of Italian children with those living in
a rural African village showed that Bacteroidetes levels (mainly Prevotella) were higher in the stool of
African children who consumed high amounts of plant polysaccharides while Enterobacteriaceae levels
were higher in the stool of Italian children [11].
Recently, exercise has also been demonstrated to modulate gut microbiota composition, showing
qualitative and quantitative modifications after running [12] in voluntary athletes.
3. Gut Microbiota and Energy Balance
3.1. Carbohydrate Metabolism
3.1.1. Animal Studies
The gut microbes can benefit the host by extracting energies from otherwise non-digestible
carbohydrates and plant polysaccharides via enzymes not encoded by humans [13]. Indeed,
indigestible polysaccharides are fermented by colonic microbiota, leading to the generation of
short-chain fatty acids (SCFAs) in the form of acetate (60%), propionate (25%), and butyrate (15%).
SCFAs are readily absorbed in the colon, where butyrate is an important energy source for colonic
epithelial cells, while acetate and propionate reach the liver and peripheral organs, where they are
used as substrates for gluconeogenesis [14].
SCFAs can also regulate gene expression by acting as signaling molecules, by binding to
G-protein-coupled receptors (GPCRs), such as GPR41 (free fatty acid receptor, FFAR3) and GPR43
(FFAR2) [15]. A recent study demonstrated that GPR43-deficient mice, even if fed with a low-fat diet,
are obese, while mice overexpressing GPR43 in adipose tissue are lean, even if under a high-fat diet
(HFD) [16]. SCFAs-dependent activation of GPR43 can modulate insulin signaling in the adipose
tissue, thus preventing fat accumulation.
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Furthermore, SCFAs directly modulate intestinal gluconeogenesis. Propionate affected intestinal
gluconeogenesis via the gut-brain neuronal circuit, involving GPR41 and butyrate through cyclic
adenosine monophosphate (cAMP)-dependent pathway, independently of GPR43 [17].
As far as butyrate is concerned, it is able to regulate the appetite via the central nervous system, by
stimulating the liberation of peptide YY (PYY) and the satietogenic hormones glucagon-like peptide 1
(GLP-1) from enteroendocrine L-cells in the distal small intestine and the colon [18]. PYY is an intestinal
hormone [19] known for its ability to decrease intestinal transit rate and increase the harvest of energy
from the diet, while GLP-1 improves adipocyte insulin sensitivity and remarkably reduces fat storage
in adipose tissue [20].
Gut microbes can also control the metabolic activity of the host by affecting the composition and
the abundance of certain bile acid species [21]. The cholic and chenodeoxycholic acids are produced in
the liver from cholesterol, and are needed for the absorption of cholesterol, dietary fats, and fat-soluble
vitamins. In the ileum microbes deconjugate these bile acids, which escape intestinal uptake, and are
converted into secondary bile acids. Bile acids can also act as signaling molecules by binding cellular
receptors, such as the bile-acid-synthesis controlling nuclear receptor farnesoid X receptor (FXR),
GPCR, and the G protein-coupled bile acid receptor TGR5 [22]. While primary bile acids can impair
glucose metabolism by binding FXR [23], secondary bile acids (deoxycholic and chenodeoxycholic
acid) improve glucose homeostasis by binding TGR5 [24] (Figure 1).
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Figure 1. Gut microbiota and energy balance. The gut microbes can benefit the host by extracting
energies from otherwise non-digestible carbohydrates and plant polysaccharides via enzymes not
encoded by humans. Short-chain fatty acids (SCFAs) modulate intestinal gluconeogenesis via the
gut-brain neuronal circuit, involving GPR41 (free fatty acid receptor, FFAR3) and through the cyclic
adenosine mo ophosphate (cAMP)-dependent pathway. Butyrate is able to regulate the appetite in the
central nervous system by stimulating the liberation of peptide YY (PYY) and the satietogenic hormone
glucagon-like peptide 1 (GLP-1) from enteroendocrine L-cells. PYY decreases the intestinal transit rate
and increases the harvest of energy from the diet, while GLP-1 improves adipocyte insulin sensitivity
and remarkably reduces fat storage in adipose tissue. Gut microbes can also control the metabolic
activity of he host by affecting the composition n the abund ce f ertain bile acid species. In the
ileum microbes deconjugate choli and chenodeox cholic acids, which escap intestinal uptake, and
are converted into secondary bile acids. Bile acids can also act as signaling molecules by binding
cellular receptors such as the bile-acid-synthesis controlling nuclear receptor farnesoid X receptor
(FXR), G-protein-coupled receptors (GPCR), and TGR5. While primary bile acids can impair glucose
metabolism by binding FXR, secondary bile acids, by binding TGR5, improve glucose homeostasis and
increase energy expenditure in skeletal muscle.
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Furthermore, animal studies demonstrated that Akkermansia muciniphila concentrations are
inversely correlated with the body weight and glucose tolerance [25]. Hansen et al. recently
demonstrated that vancomycin administration in non-obese diabetic rats increased A. muciniphila
levels and ameliorated glucose homeostasis [26].
3.1.2. Human Studies
In humans, a metagenome-wide association study demonstrated significant modifications of
specific gut microbes and metabolic pathways in T2D patients [27]. The study was performed using
stool samples of 344 Chinese patients and showed a diminution of butyrate-producing bacteria, such
as Roseburia intestinalis and Faecalibacterium prausnitzii, and an abundance of Akkermansia muciniphila.
Recently, an interesting study conducted in Europe on postmenopausal patients with normal, impaired,
or diabetic glucose regulation, showed somewhat contradictory results in comparison to the Chinese
study. Different techniques, but also ethnic and dietetic factors, can account for the discrepancy [28].
A previous, smaller study demonstrated higher levels of Lactobacillus spp. in T2D patients
in comparison to healthy controls [29] and both Chinese and European studies showed enhanced
concentration of Lactobacillus gasseri, Streptococcus mutans and certain Clostridiales, and lower levels of
Roseburia intestinalis and Faecalibacterium prausnittzii, in the diabetic cohort.
Moreover, certain antidiabetic medications can produce modification of the gut microbiota
composition. A recent paper demonstrated that metformin administration resulted in increased levels
of A. muciniphila, improvement of glucose tolerance, and reduced systemic inflammation [30,31]. In this
light, the administration of prebiotics, such as oligofructose, increased A. muciniphila concentrations
with various metabolically-beneficial outcomes [30]. In this way A. muciniphila reveals to be a promising
candidate in the understanding of the complex role of intestinal microbes in metabolic disorders even
if data are still somewhat controversial.
In summary, evidence suggests that gut microbiota plays a critical role in the energy balance by
fermentation of carbohydrates in SCFA. Gut microbiota composition appears to be involved in the




It is supposed that HFD may affect epithelial integrity, leading to impaired intestinal permeability
and, consequently, to metabolic endotoxemia and systemic inflammation [32]. Chronic exposition
to low-dose lipopolysaccharide (LPS) in mice led to hepatic fat deposition, insulin resistance
(IR), hyperlipidemia, adipose tissue macrophages infiltration, and obesity, similar as after feeding
a HFD [33,34]. Furthermore, these effects were abolished when TLR4 (Toll-like receptor, directly
involved in LPS binding) knockout mice were fed a HFD, or ob/ob mice and HFD-fed mice were
treated with antibiotics or prebiotics [32].
Another complex diet-independent effect of microbiota on host metabolism is mediated by
bacterial compounds, such as peptidoglycan and flagellin, that are able to activate inflammatory
pathways [35]. For example, TLR5 is a pattern recognizer for flagellin, which can modulate intestinal
homeostasis by activating various intracellular signaling pathways. TLR5´/´mice show a metabolic
phenotype, exhibiting gut microbiome modifications, dyslipidemia, hypertension, IR, and obesity.
Similarly to other studies, colonization of germ-free mice with TLR5´/´mice caecum microbes, led to
a metabolic phenotype [36].
Studies in rodents genetically predisposed to obesity (ob/ob), first revealed an increase in the
Firmicutes/Bacteroidetes ratio [37] and analogous differences were observed in the gut microbiota in
human obesity [37,38].
Int. J. Mol. Sci. 2016, 17, 1225 5 of 11
Interestingly, it has been clearly shown that the obese phenotype is a transmissible trait, by
transplanting the caecal microbiome from obese mice into germ-free mice who developed the same
phenotype of the donor [39,40]. Similarly, when germ-free mice were colonized with a caecum-derived
microbiome of conventional mice, the amount of the total body fat increased and insulin sensitivity
decreased [41].
A recent paper showed that colonization of germ-free mice with fecal microbiota from twin pairs
discordant for obesity resulted in an obese phenotype in mice receiving microbiota from the obese twin,
while mice receiving microbiota from the lean twin showed less weight gain and adiposity [42]. In the
same study, authors also showed that cohousing of ob/ob mice and lean mice led to the acquisition of
the gut microbiota of the lean rodents by ob/ob mice but not to the acquisition by lean mice of the ob/ob
mice microbiota. In addition, cohousing of ob/ob mice and lean mice fed with high vegetables and fruit,
a low-fat diet (LFD), resulted in a greater acquisition of microbes of the lean mice by ob/ob rodents.
A recent study showed that the increased levels of acetate in dysbiosis stimulated the
parasympathetic nervous system which, in turn, enhanced the secretion of glucose-stimulated insulin
and ghrelin, leading to hyperphagia and obesity [43].
Overall, these findings suggest an active role of gut microbiome in the development of obesity,
and the major mechanism involved appears to be the more efficient energy harvest from food [44].
3.2.2. Human Studies
Several studies demonstrated that obese patients usually show chronic adipose tissue
inflammation and that the obese-associated gut microbiome was related with a high production
of pro-inflammatory cytokines [45]. In addition, several, but not all, human adult evidence showed
a decrease of the diversity of the microbiota and an increased Firmicutes/Bacteroidetes ratio [46].
Weight loss and a LFD reversed the obese core microbiome versus the healthy microbiota, by increasing
the relative proportion of Bacteroidetes spp. and the bacterial diversity [47]. Furthermore, after
bariatric surgery, levels of Bacteroidetes and Prevotella negatively correlated with adiposity and
energy harvest [48].
Recent data on the gut fungal species of obese humans showed a reduced family biodiversity
in obese individuals but no modifications in the richness of the gut mycobiome between obese and
healthy subjects [49].
In summary, animal and human evidence described an ‘obese core microbiome’ which seems to
be involved in the pathogenesis of obesity.
3.3. Gut Microbiota and NAFLD
The first evidence for a putative role of the gut microflora in NAFLD was suggested more than
20 years ago in patients with small intestinal bacterial overgrowth (SIBO) who were prone to develop
NAFLD, and in a rat model with a blind intestinal loop in which hepatic injury was prevented by
antibiotics [50].
An human study showed an increased gut permeability and prevalence of SIBO in NAFLD
patients [51].
Recent studies focused on the increased endogenous ethanol production by the gut microbiota that
is primary involved in NAFLD development [52,53]. Indeed, ob/ob mice showed an increase in breath
ethanol amount, while normal ethanol levels were observed if mice were treated with neomycin [54].
Convincing evidence also demonstrated that the microbiota-dependent choline conversion into
methylamines in strain 129S6 on a HFD decreases the bioavailability of choline mimicking the effects
achieved by choline-deficient diets [55]. In this study, the authors observed that dietary choline
depletion induced gut microbiota modification, and that Erysipelotrichi and Gammaproteobacteria
levels were associated with changes in liver fat.
A recent study demonstrated that differences in intestinal microbiota composition could explain
the varying response to a HFD in mice [56]. In this study, two donor C57BL/6J mice were identified
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on the basis of their responses to a high-fat diet (HFD); although both groups showed similar body
weight gain, one mouse, called the ‘responder’, displayed hyperglycemia and systemic inflammation,
whereas the other, called a ‘non-responder’, was normoglycemic. When the microbiota of both groups
were transplanted into germ-free mice which were then fed with the same HFD, only mice colonized
with ‘responders’ microbiota showed hyperglycemia and fatty liver disease, in absence of systemic
and hepatic inflammation.
Moreover, an interventional study on ApoE´/´mice, a genetic model of dyslipidemia, intestinal
inflammation, and steatohepatitis, showed that the administration of the probiotic VSL#3 improved
insulin resistance, and reduced the aortic plaque extension, mesenteric adipose tissue inflammation,
and steatohepatitis [57].
A human study demonstrated that the administration of Bifidobacterium longum with
fructo-oligosaccharides, plus lifestyle modifications, were able to significantly reduce serum aspartate
transaminase (AST) levels, tumor necrosis factor (TNF)-α, CRP (C-reactive protein), HOMA-IR
(Homeostasis Assessment Model-Insulin Resistance), serum endotoxin, steatosis, and the non-alcoholic
steatohepatitis (NASH) activity index when compared to lifestyle modification alone [58].
Dysbiosis-driven inflammatory response seems to play a major role in the pathogenesis of NAFLD.
Intestinal microorganisms have highly conserved molecules, named “pathogen associated molecular
patterns” (PAMPs) which are recognized specifically by pattern recognition receptors (PRRs), such
as TLRs and nucleotide binding oligomerization domain-like receptors (NLRs). Several studies have
shown that PRR stimulation can increase pro-inflammatory cytokines and chemokines by different
intracellular signaling cascades, while commensal microbiota are able to counteract this inflammatory
response by interfering in TLR-dependent nuclear factor kappa B (NF-κB) transcription [59–61].
The multimeric signaling platforms, called ‘inflammasomes’, appear to be primarily involved in the
gut microbiota-driven liver steatosis and inflammation. The inflammasome, which is frequently
identified by its first sensing molecules, such as NLRP6 and NLRP3 (NOD-like receptors, pyrin domain
containing 6 and 3), have common pathways leading to interleukin (IL)-18 and IL-1 activation via
caspase-1 activation. Inflammasome-deficient mice showed a reduction of Firmicutes and an increase
of Bacteroidetes, associated with increased steatosis and inflammation via TLR4 and TLR9 activation,
leading to enhanced hepatic TNF-transcription [62]. Co-housing of inflammasome-deficient mice with
wild-type mice resulted in exacerbation of obesity and steatosis, concluding that NLRP6 and NLRP3
inflammasomes negatively regulate NAFLD/NASH progression. Furthermore, co-housing mice
defective in TLR4 and TLR with inflammasome-deficient mice did not worsen NAFLD/NASH [63].
In summary, evidences suggest that dysbiosis may play a critical role in the development of
NAFLD/NASH by metabolic and inflammatory pathways.
3.4. Cardiovascular Disease
Gut microbiota composition is modified not only in diabetes, obesity, and NAFLD, with adverse
cardiovascular outcomes, but also in hypertension. Indeed, animals with hypertension showed
decreased gut bacterial richness and diversity with associated reduced levels of acetate and butyrate
which negatively correlate with systemic inflammation [64]. Furthermore, several studies showed
that the “metabolic endotoxemia” caused by the exposure to LPS promoted a systemic low-grade
inflammation with an increased cardiovascular risk [65,66]. Indeed, the binding of TLR4 by LPS,
and the activation of an immune response, triggered the release of proinflammatory molecules that
promoted endothelial dysfunction, oxidation of low-density lipoproteins (LDLs), thrombogenesis, and
the formation and rupture of the atherosclerotic plaque [66].
Population studies supported a relation between infection and CVD, in consideration of
higher cardiovascular risk and blood pressure in patients affected by periodontal disease [67,68].
Mounting evidence in animals and in humans is accumulating showing that gut microbiota is
associated with CVD [69]. One study failed to show any overall difference in fecal microbiota
composition of patients with atherosclerosis, however, gut and atherosclerotic plaque microbiota
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showed several operational taxonomic units (OTUs) [70]. Indeed, atherosclerotic plaque was shown to
harbor its own microbiota dominated by Proteobacteria and Collinsella [71].
Furthermore, a meta-analysis of clinical trials of antibiotics therapy in people with atherosclerosis
failed to demonstrate their positive effect on cardiovascular mortality [72]. Nowadays, only one
prospective randomized trial with azithromycin performed for secondary prophylaxis of coronary
disease failed to reduce cardiovascular event rates [73].
Metabolomic analyses of plasma samples in humans identified novel metabolites and connecting
pathways related with cardiovascular risk [74]. Major differences were found in choline, betaine,
and trimethylamine N-oxide (TMAO), metabolites linked to phosphatidylcholine (PC) metabolism.
Choline is known to be an essential nutrient [75] and its dietary deficiency can lead to muscle damage
and liver steatosis. TMAO arises from the bacterial metabolism of choline via an intermediate
trimethylamine (TMA), which reaches the liver and is converted into TMAO by oxidizing flavin
monooxygenases 3 (FMO3) [76]. TMAO was undetectable in germ-free mice following a PC or carnitine
challenge, but conventionalization of the rodents increased TMAO levels [77]. Similarly, when mice
were treated with a cocktail of antibiotics, PC administration did not result in TMAO. Oral, but
not parental, delivery of phosphatidylcholine was associated to higher levels of TMAO, suggesting
that gut metabolic step is required for TMAO production. Interestingly, TMAO administration to
apolipoprotein E-null mice was observed to produce macrophage foam cell formation in both the
artery wall and the peritoneal cavity and to enhance aortic root atherosclerotic plaque development.
In a large cohort study of over 4000 patients undergoing elective coronary angiography, TMAO
levels were able to predict major adverse cardiac events independently from traditional CV risk
factors [78]. Blood choline and carnitine levels were also predictors of major cardiac events with respect
to stable coronary artery disease, but only when TMAO levels were concomitantly increased [76].
In summary, animal and human evidence suggest that the gut microbiota plays a contributory
role in the development of CVD but need further studies to use the gut microbiota as a new target for
prevention and treatment of CVD.
4. Concluding Remarks
Over the last years, gut microbiota has emerged as a fascinating “new organ”, involved in
many intestinal and extra-intestinal pathologies. New sequencing techniques led to the discovery
of a huge complexity of the microbiome and to the identification of potential genes involved in gut
microbiota-host interaction.
Exciting new data suggest a clear contributory role for gut microbes in cardiometabolic disorders,
such as diabetes, obesity, NAFLD/NASH, and atherosclerosis. However, more interest should be
paid to the association with metabolomics, metagenomic, and functional studies, supplemented by
prospective observational and interventional studies. The exploration of gut microbiota composition
and function has now become a field of interest that offers a new frontier to discover the complex human
host physiology and disease and providing new biomarkers and innovative therapeutic approaches.
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